MCM
ENTA icon

Matarin Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Matarin Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-28,453
Closed -$1.3M – 198
2020
Q3 		$1.3M Buy
28,453
+16,270
+134% +$788K 0.27% 135
2020
Q2 		$612K Buy
+12,183
New +$630K 0.12% 169
2020
Q1 		– Sell
-136,217
Closed -$8.41M – 217
2019
Q4 		$8.41M Sell
136,217
-64,554
-32% -$4M 0.8% 35
2019
Q3 		$12.1M Sell
200,771
-10,507
-5% -$780K 0.91% 30
2019
Q2 		$17.8M Buy
211,278
+1,875
+0.9% +$169K 1.27% 4
2019
Q1 		$20M Sell
209,403
-462
-0.2% -$41.4K 1.46% 1
2018
Q4 		$14.9M Sell
209,865
-343
-0.2% -$26.3K 1.2% 8
2018
Q3 		$18M Buy
210,208
+8,505
+4% +$852K 1.16% 12
2018
Q2 		$23.4M Sell
201,703
-21,804
-10% -$2.18M 1.69% 1
2018
Q1 		$18.1M Sell
223,507
-63,450
-22% -$4.88M 1.36% 5
2017
Q4 		$16.8M Sell
286,957
-3,664
-1% -$183K 1.31% 3
2017
Q3 		$13.6M Buy
290,621
+15,728
+6% +$632K 1.16% 6
2017
Q2 		$9.89M Sell
274,893
-71,083
-21% -$2.27M 0.92% 21
2017
Q1 		$10.7M Buy
345,976
+88,708
+34% +$2.76M 1.05% 14
2016
Q4 		$8.62M Buy
257,268
+10,420
+4% +$299K 0.97% 17
2016
Q3 		$6.57M Buy
246,848
+10,158
+4% +$236K 0.72% 44
2016
Q2 		$5.22M Buy
236,690
+17,654
+8% +$462K 0.71% 53
2016
Q1 		$6.43M Buy
219,036
+78,407
+56% +$2.18M 0.9% 24
2015
Q4 		$4.64M Buy
140,629
+93,274
+197% +$3.04M 0.69% 54
2015
Q3 		$1.71M Buy
+47,355
New +$2.03M 0.35% 97

Other funds holding ENTA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Matarin Capital Management's ENTA Position: Q4 2020 in Review

Matarin Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2020, closing a stake of 28,453 shares — an estimated $1.3M sold.

Matarin Capital Management first reported a position in ENTA in Q3 2015 and held it in 20 quarters. The position peaked at $23.4M in Q2 2018. 151 funds tracked by Wall St. Rank hold ENTA as of Q4 2020.

  • Matarin Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Matarin Capital Management sold 28,453 Enanta Pharmaceuticals shares in Q4 2020, an estimated $1.3M.
  • Matarin Capital Management first reported a position in Enanta Pharmaceuticals in Q3 2015 and held it in 20 quarters.
  • Matarin Capital Management's Enanta Pharmaceuticals position peaked at $23.4M in Q2 2018.
  • 151 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2020.

Based on Matarin Capital Management's 13F filing for Q4 2020, filed 3 Feb 2021.